TD Cowen analyst Brendan Smith raised the firm’s price target on Ginkgo Bioworks (DNA) to $16 from $10 and keeps a Buy rating on the shares. The firm provided a Q4 preview for the Life Science Tools sector where positive signs related to R&D spend, elongated sales cycles, and inventory de-stocking are likely to fight for attention with concerns over NIH, China, and policy uncertainty.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.